Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Study explores impact of altitude and anemia in children with pneumonia

Study explores impact of altitude and anemia in children with pneumonia

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare receives FDA approval for Adempas tablets

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

HOOKVAC consortium awarded grant to develop, test vaccine for human hookworm

HOOKVAC consortium awarded grant to develop, test vaccine for human hookworm

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

Scientists study genetic factors involved in complex diseases

Scientists study genetic factors involved in complex diseases

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

Ferritin protects kidneys against damage by controlling iron

Ferritin protects kidneys against damage by controlling iron

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

International team of scientists discover new disease related to inability to process Vitamin B12

International team of scientists discover new disease related to inability to process Vitamin B12

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

Anti-thrombotic therapy interruption has no influence on perioperative complications in cardiac patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.